Popular Articles
Burdock Root

Vertex Initiates Phase 3 Registration Program For VX-770, An Oral CFTR Potentiator Targeting The Defective Protein Responsible For Cystic Fibrosis
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of a Phase 3 registration program for VX-770, an investigational Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) potentiator that targets the defective CFTR protein that causes cystic fibrosis (CF). The VX-770 registration program will consist of three clinical trials, including a primary 48-week Phase 3 trial that is currently open to enrollment of patients aged 12 years and older who carry the G551D mutation on at least one allele. Two additional trials will evaluate VX-770 in patients aged 6 to 11 years with the G551D mutation on at least one allele and in patients homozygous for the F508del mutation, respectively.
generic viagra online
Fatal Injuries To Workers In Britain At Record Low, UK
The number of people killed at work in Britain has fallen to a record low, new figures from the Health and Safety Executive (HSE) reveal.
News of the day
News From The American Journal Of Pathology, June 2009
Stromal Caveolin-1 Predicts Breast Cancer Prognosis
Mental Health

Lupus Foundation Of America Seeks Proposals For Research Studies On Childhood Lupus And Stem Cell Transplantation

The Lupus Foundation of America (LFA) is seeking proposals for grant funding for research studies on lupus, an unpredictable and potentially fatal autoimmune disease. Grants will support areas of study in pediatric lupus and adult stem cell transplantation. The purposes of the studies are to advance adult stem cell transplantation research in humans as a treatment for lupus and address key understanding of pediatric/adolescent lupus research issues. This is the second year of funding for the Michael Jon Barlin Pediatric Lupus Program. There is a special urgency associated with research on pediatric lupus, as lupus in children may develop early and tends to be more severe with multi-organ system involvement. Early and aggressive treatment can have a dramatic, positive impact on disease activity and on the progression of disease. Therefore, new diagnostic and prognostic tests, as well as treatments specifically for children, are more important than ever in addressing this potentially devastating form of lupus. Stem cells are undifferentiated adult or embryonic cells that give rise to specialized cells, such as blood, bone, heart, etc. While stem cell transplantations are currently being tested and explored in clinics and labs, researchers are only beginning to understand the potential impact and role of adult stem cells in the development and treatment of lupus. Binding letters of intent must be submitted by July 13, 2009 (extended from July 3). Online applications must be submitted by August 7, 2009. Awards will be announced on September 18, 2009. For additional information, visit the research section of the LFA website at lupus.org. Although basic science and therapeutic advances are being made, substantial work remains to fully understand the causes, epidemiology, and clinical impact of lupus. The purpose of these grants is to accelerate research related to the causes, treatments, prevention and cure of lupus and to directly sponsor research to test new approaches and develop experimental therapies or treatments. The LFA"s national research program, Bringing Down the Barriers, is supported exclusively through donations from the LFA"s chapters, private foundations, corporations, and the concerned public. Lupus is an acute and chronic autoimmune disease in which the immune system is unbalanced, causing inflammation and tissue damage to virtually any organ in the body. Lupus can be unpredictable and potentially fatal, yet no satisfactory treatment or cure exists. An estimated 1.5 million Americans and at least five million people worldwide have a form of lupus. Its health effects include heart attacks, strokes, seizures, miscarriages, and organ failure. Lupus Foundation of America


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):